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Abstract
Background: Regulatory T (Treg) cells have an immunosuppressive function in cancer, but the underlying
mechanism of immunosuppression in the tumor microenvironment (TME) is unclear.
Methods: We compared the phenotypes of T cell subsets, including Treg cells, obtained from peripheral blood,
malignant effusion, and tumors of 103 cancer patients. Our primary focus was on the expression of immune
checkpoint (IC)-molecules, such as programmed death (PD)-1, T-cell immunoglobulin and mucin-domain containing
(TIM)-3, T cell Ig and ITIM domain (TIGIT), and cytotoxic T lymphocyte antigen (CTLA)-4, on Treg cells in paired
lymphocytes from blood, peritumoral tissue, and tumors of 12 patients with lung cancer. To identify the
immunosuppressive mechanisms acting on tumor-infiltrating Treg cells, we conducted immunosuppressive
functional assays in a mouse model.
Results: CD8+, CD4+ T cells, and Treg cells exhibited a gradual upregulation of IC-molecules the closer they were to
the tumor. Interestingly, PD-1 expression was more prominent in Treg cells than in conventional T (Tconv) cells. In
lung cancer patients, higher levels of IC-molecules were expressed on Treg cells than on Tconv cells, and Treg cells
were also more enriched in the tumor than in the peri-tumor and blood. In a mouse lung cancer model, IC-
molecules were also preferentially upregulated on Treg cells, compared to Tconv cells. PD-1 showed the greatest
increase on most cell types, especially Treg cells, and this increase occurred gradually over time after the cells
entered the TME. PD-1 high-expressing tumor-infiltrating Treg cells displayed potent suppressive activity, which
could be partially inhibited with a blocking anti-PD-1 antibody.
Conclusions: We demonstrate that the TME confers a suppressive function on Treg cells by upregulating IC-
molecule expression. Targeting IC-molecules, including PD-1, on Treg cells may be effective for cancer treatment.
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Background
The recent development of immune checkpoint inhibi-
tors (ICIs) has revolutionized cancer treatment. ICIs spe-
cific for anti-cytotoxic T lymphocyte antigen (CTLA)-4
or anti-programmed death (PD)-1 have improved patient
survival and have been approved for the treatment of
several cancer types, including non-small cell lung can-
cer (NSCLC), melanoma, head and neck cancer, bladder
cancer, and renal cell cancer [1–3].
The tumor microenvironment (TME) and the immune
system play critical roles in cancer progression and clin-
ical outcome [4, 5]. Regulatory T (Treg) cells are highly
immunosuppressive and contribute to the maintenance
of self-tolerance and immune homeostasis in humans [6,
7]. Treg cells infiltrate tumors and promote their pro-
gression by suppressing antitumor immunity in the
TME. Depleting Treg cells can lead to spontaneous
tumor regression due to enhanced antitumor response
[7, 8]. Interaction of Treg cells with TME enhances their
immunosuppressive function and proliferative capacity.
Several studies have shown that tumor-infiltrating Treg
cells are phenotypically distinct from those in peripheral
blood (PB) and normal tissues [9, 10], suggesting that
their immunosuppressive function depends on environ-
mental factors.
Treg cells suppressive functions are associated with the
expression of several immune checkpoint molecules
(ICs), such as PD-1, CTLA-4, T-cell immunoglobulin
and mucin-domain containing-3 (TIM)-3, and T cell Ig
and ITIM domain (TIGIT) [3, 6, 11–14]. CTLA-4 and
TIGIT act as tumor suppressors and thus, modulate the
immune response in the TME [6, 15, 16]. Although the
PD-1/PD ligand (PD-L)1 interaction was shown to pro-
mote the conversion of conventional T (Tconv) cells into
Treg cells to maintain the latter’s population [17–19], it
remains controversial whether PD-1 expression by Treg
cells suppresses antigen-specific T cell immune re-
sponses [20–22].
Recent studies have reported that IC-molecules are
upregulated on Treg cells within the TME or upon
chronic infection and that Treg cells-mediated immuno-
suppression correlates with the expression of IC-
molecules on these cells [6, 12]. The upregulation of
these molecules has also been linked to tumor progres-
sion, as it likely reinforces the suppressive function of
Treg cells in the TME. We previously reported that an
increased level of PD-1 on Treg cells during chronic viral
infection enhances CD8+ T cell immune suppression via
interaction with PD-L1 on CD8+ T cells [12]. On the
contrary, high PD-1 expression on Treg cells indicates
dysfunctional and exhausted IFN-γ-secreting Treg cells
that are enriched in tumor infiltrates and have possibly
lost their suppressive function [23]. So far, the precise
role of PD-1 in the function of tumor-infiltrating Treg
cells in the TME is controversial. Given the significance
of PD-1 in modulating immune responses and its para-
doxical role as both an activation and exhaustion
marker, clarifying the function of PD-1-positive Treg cells
and their role in regulating anti-tumor immune re-
sponses is important [23].
To evaluate the suppressive function of tumor-
infiltrating Treg cells in the TME, we comprehensively
compared the phenotypes of T cell subsets, including
Treg cells, obtained from PB, malignant effusion (ME),
and tumor (TM) samples of patients with cancer. We
also characterized Treg cells in paired lymphocyte sam-
ples obtained from blood, peri-tumoral tissue, and tu-
mors of patients with lung cancer. Using a lung cancer
mouse model, we investigated the suppressive function
and mechanism of action of tumor-infiltrating Treg cells
in the TME. We found that PD-1 was upregulated in
tumor-infiltrating Treg cells and played a role in sup-
pressing CD8+ T cell proliferation through PD-1/PD-L1
interactions. These results suggest that infiltrated PD-1-
expressing Treg cells in TME are a potential therapeutic
target for anti-cancer treatment.
Methods
Study design
Patients with stage IV cancer with ME and patients with
cancer who planned to undergo surgical resection be-
tween April 2012 and December 2017 at the Severance
Hospital were prospectively enrolled. Inclusion criteria
were as follows: 1) over 20 years old; 2) stage IV cancer
with malignant pleural effusion or ascites confirmed by
cytology, or cancer with scheduled surgery; and 3) writ-
ten informed consent. We collected 300 cc of effusions
and simultaneously obtained 10 cc of PB from patients
with stage IV cancer with ME, if available. In patients
who underwent surgery, we collected TM-adjacent nor-
mal tissue, and 10 cc of PB to isolate peripheral blood
lymphocytes (PBLs). The study was approved by the In-
stitutional Review Board of Severance Hospital. We cate-
gorized the samples into three groups: 1) PBLs, 2) ME
from patients with stage IV cancer, and 3) TM from pa-
tients with cancer who underwent surgery. To analyze
the characteristics of Treg cells in TME, we also collected
paired peritumoral tissue lymphocytes (pTILs), tumor-
infiltrating lymphocytes (TILs), and PBLs at the same
day from 12 patients with NSCLC who underwent cura-
tive resection.
Isolation of PB mononuclear cells and ME lymphocytes
PB mononuclear cells were isolated from 10 cc PB col-
lected into EDTA tubes by separation over a Percoll
(Sigma-Aldrich) gradient. Lymphocytes were isolated
from 500 cc of ME by discontinuous density gradient
centrifugation on Percoll. To isolate TILs, lung TMs
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were chopped and then incubated with a solution con-
taining 1 mg/mL collagenase type IV (Worthington Bio-
chemical) and 0.01 mg/mL DNaseI (Sigma-Aldrich) at
37 °C for 25 min. TILs were isolated by Percoll gradient
after washing dissociated tissues with ice-cold
RPMI1640.
Flow cytometry and antibodies
Flow cytometry was performed using a FACS CANTOII
(BD Biosciences, Franklin Lakes, NJ, USA) and Cyto-
FLEX (Beckman Coulter, IN, USA). Data were analyzed
using FlowJo software (Tree Star, OR, USA).
For immunolabeling of human samples, fluorophore-
conjugated monoclonal antibodies against the following
proteins were used: CD4 (RPA-T4), CD3 (OKT3), PD-1
(EH12.2H7), and CTLA-4 (BNI3) (all from Biolegend, San
Diego, CA, USA); TIM-3 (344823) and TIGIT (741182)
(both from R & D Systems, Minneapolis, MN, USA); CD25
(M-A251) (BD Biosciences, Franklin Lakes, NJ, USA); and
Foxp3 (PCH101) (eBioscience, San Diego, CA, USA). The
LIVE/DEAD Fixable Red Dead Cell Stain kit was from Invi-
trogen (Carlsbad, CA, USA). Treg cells labeled with various
antibodies (except for the antibody against Foxp3) were
fixed and permeabilized with Foxp3 fixation/
permeabilization solution (eBioscience). Foxp3 antibody
was then administered for intracellular labeling of Treg cells.
The proportion of CD4+ and CD8+ T cells among total
lymphocytes was determined, and the fraction of Foxp3-
positive CD4+ T cells was quantified.
For immunolabeling of mouse samples, fluorophore-
conjugated monoclonal antibodies against the following
proteins were used: CD4 (RM4–5), Ly5.1 (A20), PD-1
(29F.1A12), TIM-3 (RMT3–23), NK1.1 (PK136), and DX5
(DX5) (all from Biolegend); and CD8 (53-6.7), CD25
(PC61.5), CTLA-4 (UC10-4B9), TIGIT (G1GD7), and F4/
80 (BM8) (all from eBioscience); and CD11b (M1/79) (BD
Biosciences). The LIVE/DEAD Fixable Near-IR Dead Cell
Stain kit was from Invitrogen. Treg cells labeled with various
antibodies (except for the antibodies against Foxp3 and
CTLA-4) were fixed and permeabilized with Foxp3 fix-
ation/permeabilization solution (eBioscience, San Diego,
CA, USA). Foxp3 antibody was then administered for intra-
cellular labeling of Treg cells. The proportions of CD4
+ and
CD8+ T cells among lymphocytes were determined, and
the fraction of Foxp3-positive CD4+ T cells was quantified.
To prevent myeloid cells from non-specific staining, sam-
ples were preincubated with anti-CD16/32 (93)
(eBioscience) before immunolabeling with fluorophore-
conjugated antibodies.
Mouse TM model and lymphocyte isolation
Female C57BL/6, C57BL/6-Rag2−/−, and C57BL/6-Ly5.1
congenic mice (5–6 weeks) were purchased from Charles
River Laboratories (Wilmington, MA, USA) and Jackson
Laboratories (Bar Harbor, ME, USA). To generate lung
TM bearing mice, 5 × 105 TC-1 cells were intravenously
injected into C57BL/6 mice via the tail-vein. Mice were
sacrificed on day 21 post-injection. Lymphocytes were
isolated from the spleen, normal lung, and lung tumor
as previously described [9]. The number of tumor nod-
ules on left upper lobe of the lung was counted at day
12, 16, and 21 post-injection. All animal protocols were
approved by the Institutional Animal Care and Use
Committee of the Yonsei University Laboratory Animal
Research Center (2013–0115).
In vitro suppression assay using mouse lymphocytes
For the Treg cells suppression assay, CD4
+CD25+ Treg cells
(105/well) were co-cultured with CD8+ T cells (105/well)
with Dynabeads mouse T-activator CD3/CD28 (Thermo
Fisher Scientific, Waltham, MA, USA) in a 96-well U-
bottom plate at 37 °C for 72 h. For the CellTrace Violet di-
lution assay, CD8+ T cells were isolated from the spleen of
naïve mice using a CD8+ T Cell Isolation kit (Miltenyi Bio-
tec, Bergisch Gladbach, Germany) and labeled with 5 μM
CellTrace Violet (Thermo Fisher Scientific). CD4+CD25+
Treg cells were separately isolated from the spleen and
tumor of TM-bearing mice on day 21 post-injection using
CD4+CD25+ Regulatory T Cell Isolation kit (Miltenyi Bio-
tec, Bergisch Gladbach, Germany). To inhibit cell migra-
tion, Transwell membranes (0.4mm pore; BD Biosciences)
were inserted into 24-well plate. CD4+CD25+ Treg cells
(106/well) were co-cultured with CD8+ T cells (106/well)
with Dynabeads mouse T-activator CD3/CD28 (Thermo
Fisher Scientific) in a 24-well plate at 37 °C for 72 h.
For PD-1 blockade in tumor-infiltrating Treg,
CD4+CD25+ Treg cells (2.5 × 10
4/well) isolated from
tumor lymphocytes of TM bearing mice on day 14 post-
injection were preincubated with 10 μg/mL anti-PD-1
antibody (RMP1–14) or rat IgG2a isotype control (2A3)
(Bio X Cell) at 4 °C for 1 h, washed twice, and then co-
cultured with CD8+ T cells (105/well) in the presence of
mouse T-activator CD3/CD28 Dynabeads for 68 h.
Adoptive cell transfer for in vivo suppression assay
To examine the functionality of TIL Treg (PD-1
hi) and
spleen Treg (PD-1
lo) cells, CD4+CD25+ Treg cells were iso-
lated from the tumor and spleen of TM bearing mice at
day 21 post-injection using CD4+CD25+ Regulatory T Cell
Isolation kit (Miltenyi Biotec). Ly5.1+ CD8+ T cells were
isolated from naïve C57BL/6-Ly5.1 congenic mice. Ly5.1+
CD8+ T cells (2 × 106) were injected i.v. into recipient
Rag2−/− mice alone or with Ly5.2+ TIL Treg or spleen Treg
(1 × 106). At day 7 after cell transfer, splenocytes isolated
from Rag2−/− mice were analyzed for homeostatic expan-
sion of the Ly5.1+ CD8+ T cell population using FACS.
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In vitro suppression assay using human lymphocytes
CD4+CD25+ Treg cells were isolated from the tumor tis-
sue and peripheral blood of NSCLC patients, using hu-
man CD4+CD25+CD127dim/− Regulatory T Cells
Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach,
Germany). CD8+ T cells were isolated from the paired
peripheral blood of NSCLC patients using human CD8+
T Cell Isolation kit (Miltenyi Biotec, Bergisch Gladbach,
Germany) and subsequently labeled with 5 μM CellTrace
Violet. The CD8+ T cells (105/well) were co-cultured
with CD4+CD25+ Treg cells (5 × 10
4/well) isolated from
either tumor tissue or peripheral blood in the presence
of 2.5 μl/well of Dynabeads human T-activator CD3/28
(Thermo Fisher Scientific) at 37 °C for 72 h.
Multi-color immunofluorescence analysis
For multicolor immunofluorescence analysis, lungs were
isolated, fixed with 2% paraformaldehyde/phosphate buff-
ered saline overnight at 4 °C, and then embedded in OCT
compound (Sakura). Tissue blocks were frozen in 2-methyl
butane and cooled on dry ice. Frozen blocks were cut to a
thickness of 8 μm and mounted on the silane-coated slide.
Sections were stained with 4,6-diamidino-2-phenylindole
(DAPI; Invitrogen) and with antibodies for anti-CD8α
(Clone 53–6.7), anti-CD4 (clone RM4–5), anti-CD279
(clone RMP1–30), and anti-GFP (clone 1GFP63) for ampli-
fication of Foxp3-GFP signals (Biolegend). Streptavidin-
conjugated horseradish peroxidase was used for staining of
biotin-conjugated antibodies, and TSA Cyanine 3 Tyrami-
detetramethylrhodamine reagent (SAT704A001EA; Perki-
nElmer) was subsequently added for amplification. Images
was acquired using a microscope (Carl Zeiss Co. Ltd) and
analyzed with ImageJ 1.50b software.
Statistical analysis
Data were analyzed using Prism 5.0 software (GraphPad
Inc., CA, USA). The Student’s t-test, one-way analysis of
variance, and the least significant difference test were
used, where appropriate, to evaluate the significance of
differences among groups. All statistical analyses were
conducted with a significance level of α = 0.05 (P < 0.05).
Results
Patient characteristics
We enrolled 103 patients: 72 were stage IV cancer pa-
tients with ME, and 31 were patients with operable dis-
ease (not stage IV) who underwent surgical resection.
Detailed information of the patients from which PB, ME,
or TM were obtained is described in Additional file 6:
Table S1. The total number of tumor specimens was di-
vided into three groups based on the specimen type: PB,
20.7% (28/135); ME, 56.2% (76/135); and TM, 23.1%
(31/135). Detailed analyses of immune subsets as well as
the levels of their immune checkpoints were performed
in PBLs (PB group), effusion-infiltrating lymphocytes
(EILs) (ME group), and TILs (TM group). Primary can-
cer types in the ME group were NSCLC, 43.1% (31/72);
gastric cancer, 22.2% (16/72); colon cancer, 5.6% (4/72),
and breast cancer, 5.6% (4/72). The types of ME were as-
cites, 59.7% (43/76) and pleural effusion, 45.8% (33/76),
with four patients having both (Additional file 6: Table
S1). The presence of malignant cancer cells and TILs in
TM or ME was pathologically or cytologically confirmed
(Fig. 1a).
Tconv with exhausted phenotypes are abundant in TM and
ME
To investigate T cell subsets in three different tumor
specimens, we compared the ratio of CD4+ and CD8+ T
cells in PBLs, EILs, and TILs isolated from PB, ME, and
TM, respectively. The percentage of CD4+ T cells was
higher among TILs than among PBLs or EILs. In con-
trast, the percentage of CD8+ T cells was markedly lower
among TILs than among PBLs or EILs (Fig. 1b), suggest-
ing that the migration of cytotoxic lymphocytes (CTLs)
into the TM was inhibited.
The phenotypes of PBLs, EILs, and TILs were com-
pared by quantifying CD4+ and CD8+ T cells expressing
PD-1 and TIM-3. The percentage of PD-1- or TIM-3-
expressing CD4+ or CD8+ T cells was the highest among
TILs, with lower percentages in EILs and PBLs (Fig. 1c,
d), suggesting that T cells derived from TM and ME
show more pronounced T cell exhaustion than those de-
rived from PBLs.
High expression of PD-1 in Treg cells of ME and TM
We next examined how Treg cells expressing forkhead
box (Fox) p3 are distributed and differ phenotypically in
PB, ME, and TMs. Treg cells showed greater accumula-
tion in TILs than in PBLs and EILs of patients or in
PBLs of healthy controls (Fig. 2a). Interestingly, Treg cells
in TILs expressed a higher level of PD-1 than those in
PBLs and EILs; moreover, the PD-1-expressing Foxp3+
population among CD4+ T cells was also larger in TILs
than in EILs, which, in turn, had a larger population
than PBLs (Fig. 2b). To further characterize CD4+ T
cells in different tissues, we compared PD-1 in Foxp3+
and Foxp3− CD4+ T cells (Fig. 2c). The proportion of
PD-1-expressing cells in both CD4+ cells was larger in
EILs and TILs than in PBLs. These results indicate that
PD-1 expression by Treg cells and Tconv cells clearly re-
flect the TME, as PD-1 expression increased in the fol-
lowing order: TILs > EILs > PBLs.
We next investigated whether the characteristics of
CD4+ T cells, CD8+ T cells, and Treg cells were altered
in MEs depending on the cancer type. As shown in Add-
itional file 1: Figure S1, the abundance of these cells and
their expression of PD-1 in MEs were comparable in
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different types of cancer, although it is worth noting that
there were more Treg cells than there were CD4
+ or
CD8+ Tconv cells expressing PD-1. Interestingly, the de-
gree of infiltration of PD-1+ Treg cells did not differ among
ME samples derived from the different types of cancer, in-
dicating that the presence of PD-1+ Treg cells in ME is a
common feature across cancers of distinct histological ori-
gin (Additional file 1: Figure S1). Additionally, we com-
pared the phenotype of Treg between ascites and pleural
effusion. As shown in Additional file 2: Figure S2, signifi-
cant differences of the percentages of Foxp3+ Treg and
PD-1+ Foxp3+ Treg cells were not observed between
ascites and pleural effusion. Moreover, the ascites and
pleural effusions had a similar expression rate of PD-1 in
Foxp3+ Treg and Foxp3
− Tconv cells.
Tumor-infiltrating Treg are abundant in patients with lung
cancer and express multiple IC-molecules
To clarify the characteristics of Treg cells in the TME,
we compared the frequency of Treg cells and the expres-
sion of IC-molecules such as PD-1, TIM-3, TIGIT, and
CTLA-4 in paired sets of tissue-derived lymphocytes,
such as PBLs, pTILs, and TILs collected from 12 pa-
tients with NSCLC. As expected, Treg cells were
Fig. 1 T cell characteristics and PD-1 expression in Tconv of patients with cancer. Malignant effusions, such as ascites, and pleural effusions were
extracted from patients with stage IV cancer. Tumor-infiltrating lymphocytes were obtained from the tumors of patients with non-small cell lung
cancer (NSCLC) and colon cancer. a Left, computed tomography images showing malignant ascites (upper), pleural effusion (middle), and lung
cancer lesions in left lower lobe (bottom) of a patient with NSCLC. Right, cytological analysis of malignant effusion and histological analysis of
lung cancer tissue. Red arrows indicate malignant effusion and cancer (left column) and tumor cells (right column). b Proportions of CD4+ and
CD8+ T cells among CD3+ T cells. Representative plots (upper) and statistics (bottom) are shown. c, d PD-1 and TIM-3 expression on CD4+ and
CD8+ T cells. Representative plots of PD-1 and TIM-3 expression (upper) and percentages of total PD-1+ (bottom left) and TIM-3+ (bottom right)
cells among CD4+ and CD8+ T cells are shown. Peripheral blood lymphocytes (PBLs), effusion-infiltrating lymphocytes (EILs), and tumor-infiltrating
lymphocytes (TILs) were isolated from healthy control donors (HC) and patients with cancer (PBLs of HC, n = 16; PBLs, n = 28; EILs, n = 76; TILs, n =
31). Lines in the scatterplot represent the mean values. ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001 (Mann-Whitney test)
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more highly enriched in TILs than in pTILs and
PBLs (Fig. 3a). Moreover, more Treg-expressing ICs
were found among TILs than among pTILs and
PBLs (Fig. 3b).
We also compared IC-molecule expression on differ-
ent tumor-infiltrating T cell subsets. Among four differ-
ent IC-molecules, PD-1 most clearly distinguished TME
in all T cell subsets, because a significant increase in the
PD-1+ population was observed in the following order
TIL > pTIL > PBL (Fig. 3c). Notably, PD-1 was higher in
tumor-infiltrating Foxp3+Treg cells (~ 98%) than in
Foxp3−Tconv cells (~ 82%) or CD8
+ Tconv cells (78%).
Furthermore, the number of PD-1-expressing tumor-
infiltrating Foxp3+ Treg cells was greater than the num-
ber of tumor-infiltrating Foxp3+ Treg cells expressing
other IC-molecules. It is therefore conceivable that PD-1
expression on Treg cells is a TME marker. Additionally,
we performed the in vitro suppressive assay using iso-
lated CD4+CD25+ Treg cells from the peripheral blood
and tumor tissue of NSCLC patients and isolated CD8+
T cells from the peripheral blood. Each tumor-
infiltrating Treg cells or peripheral Treg cells was co-
cultured with peripheral CD8+ T cells with αCD3/CD28
stimulation. CD8+ T cells proliferated at a high rate in
the absence of Treg cells and were more potently inhib-
ited by PD-1hi tumor-infiltrating Treg cells than by PD-
1lo PBMC Treg cells (Fig. 3d).
Treg numbers and the expression of IC-molecules are
altered during cancer progression in a mouse model
We previously showed that immune-exhaustion markers
were highly expressed in tumor-infiltrating Treg cells of
patients with NSCLC. We therefore investigated the Treg
phenotype in greater detail in different tissues, using a
mouse lung cancer model. We compared the expression
levels of IC-molecules, such as PD-1, TIM-3, and TIGIT,
on CD4+ and CD8+ T cells in different tissues from
naïve and TM-bearing mice. As in patients with cancer
Fig. 2 PD-1 expression in Foxp3+ Treg in different tissue types of patients with cancer. a Representative plots of CD25 and Foxp3 expression (left)
and proportion of Foxp3+ T cells (right) among CD4+ T cells. b Representative plots of PD-1 and Foxp3 expression (left) and proportion of PD-1
and Foxp3 co-expressing cells among total CD4+ T cells (right). c Summary of PD-1-positive fraction of Foxp3+ Tconv (left) and Foxp3
− Treg (right)
cell populations among CD4+ T cells. Peripheral blood lymphocytes (PBLs), effusion-infiltrating lymphocytes (EILs), and tumor-infiltrating
lymphocytes (TILs) were isolated from healthy control donors (PBL, n = 16) and patients with cancer (PBL, n = 28; EIL, n = 76; TIL, n = 31). Lines in
the scatterplot represent the mean values. ns, not significant; **P < 0.01, ***P < 0.001 (Mann-Whitney test)
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tissue, the expression of IC-molecules in CD4+ and
CD8+ T cells was much higher in lung TM than in PB
or spleen (Fig. 4a, b). Among the populations expressing
IC-molecules, PD-1-expressing CD4+ and CD8+ T cells
were more abundant in the TM.
We next examined whether IC-molecules are pref-
erentially upregulated on Treg cells (compared to
Tconv) in TM, as was observed in patient tissues. PB,
spleen, and lung lymphocytes were isolated at differ-
ent time points after TC-1 injection (Fig. 5a). Starting
at 12 days after TC-1 injection, an increase in the
number of Foxp3+ Treg cells was observed in TM and
the Treg cells fraction reached 20% of total CD4
+ T
cells, a nearly 3-fold increase compared to that in the
non-TM lung (Fig. 5b). At 3 weeks after TC-1 injec-
tion, Foxp3+ Treg cells were more abundant in the
TM than in the PB or spleen (Fig. 5c). Foxp3+ Treg
cells in TM showed significant increases in PD-1,
TIM-3, TIGIT, and CTLA-4, compared to other tis-
sues (Fig. 5d). Moreover, tumor-infiltrating Treg cells
expressed much higher levels of IC-molecules than
tumor-infiltrating Tconv (Fig. 5e). Most Treg cells (~
80%), but only a low frequency of Tconv (~ 20%)
expressed PD-1 in TM. PD-1 was markedly upregu-
lated 21 days after TC-1 injection, and the same trend
was observed for TIM-3 and TIGIT, although the in-
creases in the levels of these molecules were less
prominent (Fig. 5f). Unlike PD-1, TIM-3, and TIGIT,
CTLA-4 was already upregulated in Treg cells before
TC-1 injection and its expression progressively in-
creased over time (Fig. 5f). Thus, expression of IC-
molecules, especially PD-1, on Treg cells increases
Fig. 3 PD-1-expressing tumor-infiltrating Treg and their activated phenotype in patients with non-small cell lung cancer (NSCLC). a CD25 and
Foxp3 expression in CD4+ T cells (upper) and proportion of Foxp3+ cells among total CD4+ T cells (lower) in peripheral blood lymphocytes (PBLs),
peritumoral infiltrating lymphocytes (pTILs), and tumor-infiltrating lymphocytes (TILs) derived from patients with NSCLC. b Representative plots of
PD-1, TIM-3, TIGIT, CTLA-4, and Foxp3 expression in CD4+ T cells (left) and percentage of CD4+ T cells co-expressing PD-1, TIM-3, TIGIT, CTLA-4,
and Foxp3 (right). c PD-1, TIM-3, TIGIT, and CTLA-4 expression in Foxp3+ Treg, Foxp3
− Tconv and CD8
+ Tconv of these patients. d Enhanced
suppression of CD8+ T cells by PD-1-expressing tumor-infiltrating Treg from NSCLC patients. Treg were isolated from the peripheral blood and
tumor tissue from NSCLC patients. Peripheral blood Treg and tumor-infiltrating Treg expressed low and high levels of PD-1, respectively. CellTrace
Violet (CTV)-labeled CD8+ T cells were stimulated in vitro with CD3/CD28 Dynabeads for 96 h in the absence or presence of each Treg population.
CTV dilution in proliferating CD8+ T cells is indicated in each histogram. Histograms represent the percentages of proliferating cells. Lines in the
bar graph represent the mean and mean ± SEM, respectively. ns, not significant; **P < 0.01, ***P < 0.001 (Mann-Whitney test)
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with TM progression. As tumor numbers increased,
immune checkpoints including PD-1, TIM-3, TIGIT,
and CTLA-4 increased (Additional file 3: Figure S3).
Immunosuppressive function of tumor-infiltrating Treg in
CD8+ T cell response is mediated by PD-1/PD-L1
interaction
Among all IC-molecules examined, PD-1 was most
highly upregulated in tumor-infiltrating Treg cells. To
determine the role of PD-1 on tumor-infiltrating Treg
cells, in the regulation of the CD8+ T cell response, we
compared the suppressive activity of Treg expressing
high- and low-levels of PD-1 (PD-1hi Treg cells from lung
TM 3weeks after TC-1 injection vs. PD-1lo Treg cells
from the spleen of the same TM-bearing mice).
CD4+CD25+ Treg cells, isolated using a microbead-based
Treg isolation kit (CD4+CD25+ Regulatory T Cell Isola-
tion kit), was confirmed to be ~ 90% purified Foxp3+
Treg cells (Additional file 4: Figure S4). Each population
was co-cultured with naïve CD8+ cells with or without
stimulation by αCD3/CD28. CD8+ T cells proliferated at
a high rate in the absence of Treg cells and were more
potently inhibited by PD-1hi tumor-infiltrating Treg cells
than by PD-1lospleen Treg cells (Fig. 6a). Similarly, inter-
feron (IFN)-γ production was also more strongly sup-
pressed by PD-1hi tumor-infiltrating Treg than by PD-1
lo
spleen Treg cells.
To investigate the role of PD-1 upregulation, induced
by tumor-infiltrating Treg cells, we examined whether
the interaction between PD-1 on tumor-infiltrating Treg
cells and PD-L1 on CD8+ T cells is required for im-
munosuppression in patients with cancer. PD-1 on
tumor-infiltrating Treg cells was blocked by incubation
with an anti-PD-1 antibody. Unbound antibody was sub-
sequently removed and the cells were co-cultured with
CD8+ T cells. We prepared Treg cells, expressing an
intermediate level of PD-1 that were isolated from lung
TM in 2- rather than in 3-weeks after injection because
Treg cells, highly expressing PD-1, isolated at later time-
points, also co-expressed other IC-molecules (Fig. 5),
making it difficult to differentiate the role of PD-1 in the
suppressive function of Treg cells from that of others.
Additionally, to clarify whether the potent suppressive
function of PD-1hi tumor-infiltrating Treg cells is medi-
ated via cell-to-cell contact between Treg and CD8
+ cells
or soluble factors produced from Treg cells, we con-
ducted the experiments with transwell membrane system
to block cell migration (Fig. 6b). Transwell membranes
were inserted into 24-well plate. CTV labeled CD8+ T
cells and CD4+CD25+ Treg were placed into lower and
upper wells, respectively, and αCD3/CD28 was added
into both wells for stimulation. Suppression of T cell
proliferation was not observed in the presence of the
Transwell membrane. This data demonstrated that the
suppression of CD8+ T cell proliferation by Treg requires
cell to cell contact between each cell population (Fig.
6b). Next, we performed the in vivo experiment with
TIL Treg and spleen Treg cellsalong with Ly5.1
+CD8+ T
cells. In line with in vitro data, when TIL Treg cells was
injected, CD8+ T cell proliferation was significantly
Fig. 4 Differential expression of immune checkpoint (IC) molecules on CD4+ and CD8+ T cells in mice with lung cancer. To induce lung
adenocarcinoma, TC-1 cells were intravenously injected into syngeneic mice. a, b Tumor-bearing mice at 3 weeks after TC-1 cell injection and
naïve control mice were sacrificed, and lymphocytes were isolated from peripheral blood (PB), spleen (SP), and lung (LG). (Left) Expression levels
of PD-1, TIM-3, and TIGIT on CD4+ and CD8+ T cells were assessed. (Right) Summary of the proportions of IC molecules expressed on populations
of CD4+ and CD8+ T cells in PB, SP, and LG at the tumor site. Numbers in the plot indicate percentages of the corresponding population. Data
are representative of three independent experiments (n = 5 mice per group in each experiment). ns, not significant; *P < 0.05, **P < 0.01, ***P <
0.001 (Student’s t-test). The symbol above each column is the P value obtained when SP samples were compared to the corresponding samples
from naïve mice (control)
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inhibited compared with spleen Treg and no Treg cells
(Fig. 6c).
As shown in Fig. 6d, tumor-infiltrating Treg cells that
had been blocked with anti-PD-1 antibody, were signifi-
cantly impaired in their ability to suppress the prolif-
eration of CD8+ T cells and IFN-γ production as
compared to isotype antibody-treated tumor-
infiltrating Treg cells. Given that both mouse and hu-
man CD8+ T cells can upregulate low affinity Fc re-
ceptors following activation [24, 25], we tested
whether CD8+ T cells upregulate Fc receptors in our
system. We obtained splenocytes of TC-1 tumor bear-
ing mice. We stained splenocytes with CD8, CD44,
CD16/32 (FcγRIII/II), and CellTrace Violet and com-
pared the expression of Fc receptor between with and
without stimulation. Significant differences of CD16/
32 were not observed between groups with and with-
out stimulation (Additional file 5: Figure S5A). To
validate the CD16/32 antibody, we analyzed the ex-
pression of CD16/32 on NK cells and macrophages.
This antibody can specifically detect CD16/32 on
these cells, so we excluded the possibility that no de-
tection of CD16/32 on CD8+ T cells after stimulation
could be a problem of CD16/32 antibody (Additional
file 5: Figure S5B). Taken together, our data demon-
strated that the effect of anti-PD-1 is direct effect by
Fig. 5 Spatial and temporal dynamics of immune checkpoint (IC) molecule expression on Treg during cancer progression. a Schedule for
establishing the TC-1 lung adenocarcinoma model and tumor formation at each time point. b Representative plots showing CD25 and Foxp3
expression in CD4+ T cells (left) and changes at different time points after TC-1 TM tumor cell injection (right). c Representative plots of Treg (left)
and summary of the proportion of Foxp3+ cells among CD4+ T cells (right) in peripheral blood (PB), spleen (SP), and lung (LG). d Levels of PD-1,
TIM-3, TIGIT, and CTLA-4 expression on Foxp3+CD4+ Treg in PB, SP, and LG. e Levels of PD-1, TIM-3, TIGIT, and CTLA-4 expression on Treg and Tconv
in different tissues (PB, SP, and LG). f Changes in the levels of PD-1, TIM-3, TIGIT, and CTLA-4 expression on Treg at different time points. Data are
representative of three independent experiments (n = 5 mice per group in each experiment). ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001
(Student’s t-test)
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blocking of PD-1 pathway signaling rather than the
effect of anti-PD-1 antibody mediated by ADCC.
A multi-color immunofluorescence analysis revealed
that CD8, PD-1, and Foxp3 were co-localized in mouse
tumor tissues (Fig. 6e), implying that CD8+ cells and
Foxp3+ Treg cells spatially interact in the TME.
Discussion
In this study, we examined the phenotype and func-
tion of Treg cells as well as CD4
+ and CD8+ Tconv
cells that infiltrated into the TME, including the ME
and TM from patients with cancer. We also investi-
gated the mechanism by which Treg cells induce
immunosuppression using a mouse lung cancer
model. Most tumor-infiltrating Treg cells showed
higher PD-1 expression than Tconv cells, implying that
PD-1-expressing Treg cells are a biological marker of
the TME. Indeed, in Treg cells derived from TMs of
patients with NSCLC, PD-1 was the most clearly up-
regulated IC-molecule. As previously reported, these
cells exhibited an enhanced immunosuppressive func-
tion that was correlated with the extent of PD-1 up-
regulation [12]. We speculate that PD-1-expressing
tumor-infiltrating Treg cells induce immunosuppres-
sion through the interaction of PD-1 and PD-L1,
which may contribute to immune escape in TME.
Fig. 6 Enhanced suppressive function of PD-1-expressing tumor-infiltrating Treg. a Enhanced suppression of CD8
+ T cells by PD-1-expressing
tumor-infiltrating Treg. At 3 weeks after intravenous injection of TC-1 cells, Treg were isolated from the spleen (SP) and lung of mice with TC-1 cell-
induced tumors. SP Treg and tumor-infiltrating Treg expressed low and high levels of PD-1, respectively. CellTrace Violet (CTV)-labeled CD8
+ T cells
were stimulated in vitro with CD3/CD28 Dynabeads for 72 h in the absence or presence of each Treg population. CTV dilution in proliferating
CD8+ T cells is indicated in each histogram. Histograms represent the percentages of proliferating (upper) and IFN-γ-producing (lower) cells. b
Contact-dependent Treg-mediated suppression of CD8
+ T proliferation. CTV-labeled CD8+ T cells were stimulated in vitro with CD3/CD28
Dynabeads and cocultured with tumor-infiltrating Treg for 72 h in the absence or presence of a transwell membrane. c Homeostatic proliferation
of donor Ly5.1+CD8+ T cells in the spleen isolated from Rag2−/− mice at 7 d after adoptive cell transfer. Representative plot (left) and absolute
number (right) of donor Ly5.1+CD8+ T cells in the spleen. d PD-1-mediated suppressive activity of tumor-infiltrating Treg isolated from the lungs
of tumor-bearing mice 2 weeks after intravenous injection of TC-1 cells. At this time point, Treg expressed intermediate levels of PD-1. CTV-labeled
CD8+ T cells were stimulated as shown in (a). Before co-culture of CD8+ T cells with tumor-infiltrating Treg, the latter were pre-incubated with an
anti-PD-1 antibody or its isotype as control. CTV dilution in proliferating CD8+ T cells is shown in the histograms, which represent the
percentages of proliferating (upper) and IFN-γ-producing (lower) cells. (e) Representative immunofluorescence images of mouse lung tumor
samples. Antibodies against Foxp3, CD8, and PD-1 were used to label and examine the interaction between Treg and CD8
+ T cells expressing PD-
1. Data are representative of two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test)
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Clarifying the link between this phenotype and en-
hanced suppressive function of tumor-infiltrating Treg
cells can provide insight into their suppressive mech-
anism in patients with cancer.
The predominant function of PD-1 in Treg cells seems
to be similar to that of CTLA-4; both proteins contrib-
ute to the maintenance of Treg immunosuppressive func-
tion [15]. However, PD-1 expression on Treg cells
differed by cell location. For instance, PD-1 was
expressed by Treg cells in TMs but not in normal tissue
or PBLs as depicted in Fig. 3. In contrast, Treg cells had
high basal CTLA-4 levels irrespective of the tissue of ori-
gin. This supports our assertion that PD-1 on Treg cells
is a more useful marker for characterizing the TME. We
also examined whether the upregulation of PD-1 on
tumor-infiltrating Treg cells can reinforce their basal
immune-suppressive function. High PD-1 expression in
Treg cells was associated with the suppression of CD8
+ T
cells and PD-1 blockade abrogated the immune-
suppressive function of Treg cells, suggesting that an
interaction between PD-1 on Treg cells and PD-L1
expressed by another cell type—likely CD8+ T cells
[26]—is necessary for immunosuppression. Thus, ele-
vated PD-1 expression on Treg cells is a potential marker
for immune escape in patients with cancer. These find-
ings were consistent with our previously reported data
that PD-1 upregulation in Treg cells and the interaction
between PD-1 on Treg cells and PD-L1 expressed by ef-
fector T cells enhanced T cell-mediated immune sup-
pression during chronic viral infection [12]. Thus, an
immunotherapy targeting Treg and PD-1 could be highly
effective in patients with cancer.
We also investigated tumor-infiltrating Treg and Tconv
cells obtained from ME of patients with stage IV cancer.
Most of the earlier studies of TME Treg cells were per-
formed in mice and focused on Treg cells phenotype.
Studies in patients with stage IV cancer have been ham-
pered by the difficulty of obtaining sufficient TMs for
analysis of T cell populations. To overcome this limita-
tion, we developed an experimental model using ME
from human patients with stage IV cancer as representa-
tive TME of stage IV cancer. This model will allow fu-
ture examinations of various mechanistic aspects of
human cancer through functional assays.
Several studies have reported IC expression on intra-
tumoral Treg cells and suggested potential roles of these
ICs in the regulation of the immune response in mice [6,
15, 27]. We also showed here that ICs other than PD-1
were upregulated in Treg cells. Studies on the relative
contributions of these IC-molecules to immunosuppres-
sion in the TME may lead to the development more ef-
fective immunotherapies.
Regarding other PD-1-expressing immune cells than
CD8+ T cells and Treg cells in TME and their role, Irving
et al. reported that tumor-associated macrophages (TAMs)
expressed PD-1 and PD-1-expressing TAMs increased over
time in mouse model and progressive disease in human
cancers [28]. PD-1 expressed on TAMs reduced their
phagocytic potency against tumor cells and blockade of
PD-1 pathway restored the macrophage phagocytosis,
resulting in enhancing anti-tumor activity of TAMs. This
data suggests that PD-1 expressed by TAMs is one of the
mechanism for immune evasion. PD-1 expression was also
described on NK cells in many different types of human
and mouse cancers, where the PD-1 expressed by NK cells
negatively regulated NK cell function even though its mo-
lecular mechanisms are not clearly demonstrated to date
[29–34]. In addition, PD-1 has been reported to be
expressed on innate lymphoid cells (ILCs), prevalently ILCs
type 3 (ILC3s), as well as NK cells in pleural effusion of pri-
mary and metastatic tumors, albeit the role of PD-1 on
ILC3s was not addressed [35].
Based on these reports, it is plausible that PD-1 expressed
by different types of immune cells including CD8+ T cells,
Treg cells, NK cells, and ILCs in the TME probably contrib-
utes to immune evasion, leading to promotion of tumor
cells. However, it has not been addressed yet which types of
PD-1-expressing immune cells are most effectively involved
in the PD-1-mediated immunosuppression. In addition, to
compare the immunosuppressive activity of each immune
cell subset, the level of PD-1 expression on each type of cells
should be examined. In this regard, further study is needed
to determine whether other PD-1-expressing immune cells
than Treg cells in the TME compensate for a lack of Treg
cells and which types of PD-1-expressing immune cells
mostly impact on immune suppression in the TME.
Treg cells expansion in the TME is widely recognized
as an obstacle to successful immunotherapy in patients
with cancer [5]. Previously, we demonstrated that Treg
cells depletion using an anti-CD25 antibody increased
the abundance of functional antigen-specific CD8+ T
cells during chronic viral infection [12]. Furthermore,
treatment with a neutralizing antibody also caused the
elimination of non-Treg and rapid replenishment of Treg
cells [36]. Thus, functional inactivation of Treg cells and
rejuvenation of exhausted T cells by targeting overex-
pressed PD-1 combined with temporal depletion of Treg
cells expressing IC-molecules may be a promising strat-
egy to limit cancer progression.
Conclusions
In conclusion, our study provides insights into Treg cells
function and their suppressive mechanism in patients
with cancer. We showed that the suppressive function of
tumor-infiltrating Treg cells was enhanced by the in-
crease in their relative proportion and by the upregula-
tion of the expression of inhibitory receptors, such as
PD-1, TIM-3, and CTLA-4.
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Additional file 1: Figure S1. PD-1 expression on CD4+, CD8+, or Treg in
malignant effusion according to the different types of cancer patients in-
cluding lung cancer, gastric cancer, breast cancer, and others.
Additional file 2: Figure S2. Comparison of Treg phenotype between
ascites and pleural effusion. (A) Percentage of Foxp3 in total CD4+ T cells
between ascites and pleural effusion (B) Percentage of PD-1+Foxp3+ in
total CD4+ T cells between ascites and pleural effusion (C) Percentage of
PD-1+ in Foxp3+CD4 Treg between ascites and pleural effusion (Left), per-
centage of PD-1+in Foxp3− CD4 T cells between ascites and pleural
effusion.
Additional file 3: Figure S3. Correlation of the immune checkpoint
including PD-1, TIM-3, TIGIT and CTLA4 expressed on Treg as tumor nod-
ule number increased. (A) PD-1, (B) TIM-3, (C) TIGIT, and (D) CTLA-4 ex-
pression on Treg according to the increased tumor nodules. The number
of tumor nodules was measured at day 12, 16, and 21 post-injection (n =
4–7 mice per group). Data are representative of two independent experi-
ments. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test).
Additional file 4: Figure S4. Purification of tumor-infiltrating Treg using
microbead-based Treg isolation kit. Treg were separately isolated from the
spleen and from TM-bearing mice using a CD4+CD25+ Regulatory T Cell
Isolation kit for suppressive function analysis. Treg, isolated using a
microbead-based Treg isolation kit, demonstrated ~ 90% purified Foxp3+
Treg compared with the 16% prior to isolation.
Additional file 5: Figure S5. Expression of CD16/32 on CD8+ T cells
after in vitro TCR activation and NK cells and macrophages. (A) The
expression of CD16/32 on purified CD8+ T cells activated by CD3/28
Dynabeads for 3 d. (B) The expression of CD16/32 on Dx5+NK1.1+ NK
cells and CD11b+F4/80+ macrophages isolated from the spleen of naïve
mouse.
Additional file 6: Table S1. Baseline characteristics of patients and
specimens.
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